Market share for Ingrezza vs. Austedo in tardive dyskinesia (2025)
I don’t have any 2025 market-share figures for Ingrezza (valbenazine) or Austedo (deutetrabenazine) in the information provided. If you share the source you’re working from (for example, a report, slide deck, payer dataset, or article excerpt), I can extract the exact market-share numbers and format them for 2025.
Why 2025 market-share numbers can vary by source
When people search “market share … 2025” for tardive dyskinesia therapies, the reported share can differ depending on what the dataset measures:
- Prescriptions or script units vs. patient counts
- Retail vs. total channels (including specialty pharmacy)
- A specific geography (U.S. only vs. global)
- Brand-only share vs. total treatment share including generics (if any comparators are counted)
- The time window (calendar year 2024 vs. trailing 12 months leading into 2025)
If you tell me which definition your source uses, I can help reconcile why two numbers might not match.
How to find reliable 2025 share estimates (and what to look for)
For the most “search-intent aligned” results, look for sources that publish:
- A year-specific topline (e.g., “2025 YTD” or “2025 full-year”)
- A clear denominator (TM (total market) units/patients)
- A breakdown by drug (Ingrezza vs. Austedo) and sometimes by payer mix
If you want, paste a link or excerpt and I’ll pull out the exact market-share figures and cite them cleanly.
Patent/exclusivity context (often requested alongside market share)
Market-share discussions for VMAT2 inhibitors like Ingrezza and Austedo are commonly tied to exclusivity and patent timelines. If you want those details for the 2025 competitive backdrop, DrugPatentWatch.com is a useful place to check for relevant filings and expiration estimates: https://www.drugpatentwatch.com/
Quick clarification so I can answer precisely
Do you mean:
1) U.S. market share for tardive dyskinesia drugs in 2025, or global?
2) Market share by prescriptions (scripts), by patients, or by revenue?
3) “Ingrezza vs Austedo” only, or should I include other tardive dyskinesia treatments too?
Sources cited: none (no provided data).